JP7246927B2 - 質量分析キット - Google Patents

質量分析キット Download PDF

Info

Publication number
JP7246927B2
JP7246927B2 JP2018544901A JP2018544901A JP7246927B2 JP 7246927 B2 JP7246927 B2 JP 7246927B2 JP 2018544901 A JP2018544901 A JP 2018544901A JP 2018544901 A JP2018544901 A JP 2018544901A JP 7246927 B2 JP7246927 B2 JP 7246927B2
Authority
JP
Japan
Prior art keywords
fragment
immunoglobulin
light chain
antibody
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018544901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509483A (ja
JPWO2017144900A5 (enExample
Inventor
エル．マーレイ デイビッド
ハーディング スティーブン
アール．バーニッジ デイビッド
ウォールズ グレッグ
ミルズ ジョン
アシュビー ジェイミー
Original Assignee
ザ バインディング サイト グループ リミティド
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7246927(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ザ バインディング サイト グループ リミティド, メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ filed Critical ザ バインディング サイト グループ リミティド
Publication of JP2019509483A publication Critical patent/JP2019509483A/ja
Priority to JP2022017497A priority Critical patent/JP7541045B2/ja
Priority to JP2022198753A priority patent/JP7541070B2/ja
Publication of JPWO2017144900A5 publication Critical patent/JPWO2017144900A5/ja
Application granted granted Critical
Publication of JP7246927B2 publication Critical patent/JP7246927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
JP2018544901A 2016-02-25 2017-02-24 質量分析キット Active JP7246927B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022017497A JP7541045B2 (ja) 2016-02-25 2022-02-07 質量分析キット
JP2022198753A JP7541070B2 (ja) 2016-02-25 2022-12-13 質量分析キット

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1603291.4 2016-02-25
GBGB1603291.4A GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies
US201662368606P 2016-07-29 2016-07-29
US62/368,606 2016-07-29
PCT/GB2017/050489 WO2017144900A1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022017497A Division JP7541045B2 (ja) 2016-02-25 2022-02-07 質量分析キット
JP2022198753A Division JP7541070B2 (ja) 2016-02-25 2022-12-13 質量分析キット

Publications (3)

Publication Number Publication Date
JP2019509483A JP2019509483A (ja) 2019-04-04
JPWO2017144900A5 JPWO2017144900A5 (enExample) 2022-12-26
JP7246927B2 true JP7246927B2 (ja) 2023-03-28

Family

ID=55806928

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018544901A Active JP7246927B2 (ja) 2016-02-25 2017-02-24 質量分析キット
JP2022017497A Active JP7541045B2 (ja) 2016-02-25 2022-02-07 質量分析キット
JP2022198753A Active JP7541070B2 (ja) 2016-02-25 2022-12-13 質量分析キット

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022017497A Active JP7541045B2 (ja) 2016-02-25 2022-02-07 質量分析キット
JP2022198753A Active JP7541070B2 (ja) 2016-02-25 2022-12-13 質量分析キット

Country Status (12)

Country Link
US (1) US12461108B2 (enExample)
EP (2) EP4123308A1 (enExample)
JP (3) JP7246927B2 (enExample)
KR (1) KR102851057B1 (enExample)
CN (2) CN116148479A (enExample)
AU (1) AU2017222399B2 (enExample)
BR (1) BR112018067435A2 (enExample)
CA (1) CA3015296A1 (enExample)
DK (1) DK3420361T3 (enExample)
ES (1) ES2936783T3 (enExample)
GB (1) GB201603291D0 (enExample)
WO (1) WO2017144900A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708262D0 (en) 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease
SG11202108033TA (en) * 2019-01-31 2021-08-30 Regeneron Pharma Native microfluidic ce-ms analysis of antibody charge heterogeneity
CN110009008B (zh) * 2019-03-18 2020-11-06 四川大学 基于提取的免疫固定电泳图特征对其进行自动分类的方法
GB201906599D0 (en) 2019-05-10 2019-06-26 Binding Site Group Ltd Mass spectrometry calibrator
CN113811772B (zh) * 2019-05-10 2024-12-06 结合点集团有限公司 质谱分析校准物
GB201915946D0 (en) 2019-11-01 2019-12-18 Binding Site Group Ltd Quantitation of immunoglobulins i n mass spectrometry
GB202007047D0 (en) * 2020-05-13 2020-06-24 Binding Site Group Ltd Mass spectrometry controls
GB202008887D0 (en) * 2020-06-11 2020-07-29 Binding Site Group Ltd A method of identifying or characterising an immune response in a subject
GB202016822D0 (en) 2020-10-23 2020-12-09 Binding Site Group Ltd Quantitation of immunoglobulins in mass spectrometry
CN113720900A (zh) * 2021-09-14 2021-11-30 首都医科大学附属北京朝阳医院 一种基于madli-tof ms技术检测血清中m蛋白的方法
CN114324557B (zh) * 2021-12-03 2024-05-10 融智生物科技（青岛）有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154052A1 (en) 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
WO1991006570A1 (en) * 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ATE294959T1 (de) * 1994-05-13 2005-05-15 Miltenyi Biotec Gmbh An protein gebundene sterile und pyrogenfreie säulen zum binden und entfernen von substanzen aus blut
JP2826965B2 (ja) * 1995-01-12 1998-11-18 オリエンタル酵母工業株式会社 免疫吸着体とその製造法
DE69634092T2 (de) 1995-11-03 2005-12-08 The Binding Site Ltd. Herstellung von antikörpern
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
KR20070007253A (ko) * 2003-10-08 2007-01-15 이바이오사이언스 천연 면역글로불린 결합 물질 및 이의 제조 방법 및 사용방법
WO2006099481A2 (en) 2005-03-14 2006-09-21 Medimmune, Inc. Macromolecules comprising a thioether cross-link
DE602006020850D1 (de) 2005-04-12 2011-05-05 Akira Matsumori Biomarker zur diagnose einer herzerkrankung sowie verwendung davon
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
WO2008079914A1 (en) 2006-12-21 2008-07-03 Novartis Ag Antibody quantitation
RU2012118620A (ru) 2009-10-09 2013-11-20 Симфоген А/С Множественное количественное определение в смеси индивидуальных рекомбинантных белков посредством сигнатурных пептидов и масс-спектрометрии
GB201001946D0 (en) 2010-02-05 2010-03-24 Binding Site Group The Ltd Cancer prognostic assay
GB2478520A (en) 2010-03-02 2011-09-14 Binding Site Group Ltd Kidney prognostic assay
GB201117172D0 (en) 2011-10-05 2011-11-16 Binding Site Group The Ltd Diabetes
GB201121265D0 (en) 2011-12-12 2012-01-18 Binding Site Group The Ltd Assay
US20150031861A1 (en) 2012-03-09 2015-01-29 Ucl Business Plc Chemical Modification of Antibodies
WO2014121031A1 (en) 2013-01-31 2014-08-07 Excelimmune, Inc. Characterization of antibody mixtures by mass spectrometry
WO2015131169A2 (en) * 2014-02-28 2015-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Personalized myeloma detection
US10690676B2 (en) * 2014-07-29 2020-06-23 Mayo Roundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by LC-MS/MS
AU2015334455B2 (en) * 2014-10-21 2020-05-21 Gennova Biopharmaceuticals Limited A novel purification process for isolation and commercial production of recombinant TNK-tPA (Tenecteplase)
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154052A1 (en) 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｍｉｃｈｅｌ Ｇｏｌｄｂｅｒｇ ｅｔ ａｌ．，Ｓｐｅｃｉｆｉｃ ｉｎｔｅｒｃｈａｉｎ ｃｒｏｓｓｌｉｎｋｉｎｇ ｏｆ ａｎｔｉｂｏｄｉｅｓ ｕｓｉｎｇ ｂｉｓｍａｌｅｉｍｉｄｅｓ．，Ｂｉｏｃｏｎｊｕｇａｔｅ Ｃｈｅｍｉｓｔｒｙ，１９９１年，Ｖｏｌ．２， Ｎｏ．４，ｐｐ．２７５－２８０
Ｒｏｂｅｒｔ Ｆ． Ｓｔｅｉｎｈｏｆｆ ｅｔ ａｌ．，Ｍｉｃｒｏａｒｒａｙ－ｂａｓｅｄ ＭＡＬＤＩ－ＴＯＦ ｍａｓｓ ｓｐｅｃｔｒｏｍｅｔｒｙ ｅｎａｂｌｅｓ ｍｏｎｉｔｏｒｉｎｇ ｏｆ ｍｏｎｏｃｌｏｎａｌ，Ｍｅｔｈｏｄｓ，２０１５年１２月１８日，Ｖｏｌ．１０４，ｐｐ．３３－４０
日本生化学会編，新生化学実験講座１２ 分子免疫学ＩＩＩ－抗原・抗体・補体－，１９９２年，第１版，３０－３１頁

Also Published As

Publication number Publication date
AU2017222399A1 (en) 2018-08-30
JP7541045B2 (ja) 2024-08-27
CN108885218A (zh) 2018-11-23
KR20180132651A (ko) 2018-12-12
GB201603291D0 (en) 2016-04-13
EP3420361B1 (en) 2023-01-04
US20190094239A1 (en) 2019-03-28
CN116148479A (zh) 2023-05-23
US12461108B2 (en) 2025-11-04
AU2017222399B2 (en) 2024-03-14
BR112018067435A2 (pt) 2019-01-02
JP2019509483A (ja) 2019-04-04
EP3420361A1 (en) 2019-01-02
EP4123308A1 (en) 2023-01-25
JP2023033281A (ja) 2023-03-10
DK3420361T3 (da) 2023-01-23
WO2017144900A1 (en) 2017-08-31
JP7541070B2 (ja) 2024-08-27
KR102851057B1 (ko) 2025-08-28
ES2936783T3 (es) 2023-03-22
JP2022069446A (ja) 2022-05-11
CA3015296A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
JP7541070B2 (ja) 質量分析キット
US20230080943A1 (en) Assay for plasma cell associated disease
US20230391851A1 (en) Antibodies
CN113811772B (zh) 质谱分析校准物
HK40087264A (en) Mass spectrometry kit
HK40081916A (en) Assay for plasma cell associated disease
RU2281510C1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИ РЕАГИРУЮЩИЕ С ПРИОННЫМ ПРОТЕИНОМ PrP ИЛИ ЕГО ФРАГМЕНТОМ, И ИХ ПРИМЕНЕНИЕ
KR20230029629A (ko) 질량 분석법 컨트롤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220207

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220207

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220222

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220324

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220329

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220422

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220510

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220719

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220913

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221004

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221213

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230124

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230221

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230315

R150 Certificate of patent or registration of utility model

Ref document number: 7246927

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157